Vigilant Biosciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Vigilant Biosciences is a private, commercial-stage diagnostics company pioneering a novel point-of-care test for the early detection of oral cancer. Its flagship product, the BeVigilant OraFusion System, utilizes patented biomarker technology to provide real-time screening in dental settings. The company has achieved significant regulatory milestones, including FDA Breakthrough Device Designation and IVDR approval for international expansion, and is now preparing for a pivotal US clinical trial to support FDA marketing authorization. Vigilant aims to address a critical unmet need in oncology by shifting diagnosis to earlier stages, where survival rates are significantly higher.

OncologyOral Cancer

Technology Platform

Patented point-of-care diagnostic system (BeVigilant OraFusion) that detects specific salivary biomarkers clinically associated with oral cancer.

Opportunities

The large, global unmet need for early oral cancer detection presents a significant market opportunity, particularly through dental practices and consolidating Dental Service Organizations (DSOs).

Successful US FDA authorization, following the upcoming pivotal trial, would unlock the world's largest healthcare market.

International expansion, already underway with IVDR approval, provides a near-term revenue stream and clinical experience.

Risk Factors

The company faces substantial regulatory risk, as US commercialization depends entirely on the outcome of its pivotal trial and subsequent FDA review.

Commercial adoption risks include the challenge of changing clinical practice in a fragmented dental market and securing adequate insurance reimbursement.

Competition from other emerging screening technologies and reliance on a single product pipeline also pose threats.

Competitive Landscape

Vigilant appears to be a first-mover with a specific FDA-designated point-of-care test for oral cancer detection. Competition includes other adjunctive screening aids like advanced visualization devices (e.g., VELscope), other salivary biomarker tests, and cytology brushes. The competitive landscape is fragmented, but Vigilant's combination of biomarker science, point-of-care design, and regulatory progress provides a differentiated position.

More companies in Diagnostics & Precision Medicine →More companies in United States →